Press Release - Company Data

Amorfix Appoints Dr Elliot Goldstein and Mr Warren Whitehead to Board of Directors
Posted 2014-09-04 00:05NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Dr. Elliot Goldstein and Mr.

Amorfix Announces Retirement of Dr. Hans Black
Posted 2014-08-20 00:07NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that Dr. Hans Black has retired from the Board of Directors.

Amorfix awarded broad United States patent for misfolded SOD1-targeted treatment of ALS
Posted 2014-07-16 00:04NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that the company has been issued a broad patent covering antibodies that target mi

William Wyman Appointed Amorfix Chairman of the Board
Posted 2014-06-11 23:38NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that Mr. William Wyman has been appointed Chairman of the Board. Dr.

Amorfix Closes Private Placement Offering
Posted 2014-04-27 23:49NAI Editing
announces that it has closed the third tranche of a non-brokered private placement (the Offering) pursuant to which 333,333 common shares of Amorfix (Shares) and 333,333 Warrants were issued for gross

Former Amorfix Board member Walter Von Wartburg to act as Board advisor
Posted 2014-03-19 23:46NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that former board member Dr.

Amorfix and Trellis Bioscience to Collaborate on Anti-CD38 Antibody Treatment for Cancer
Posted 2014-03-16 23:32NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has entered into a collaboration with Trellis Bioscience to develop antib

Amorfix Appoints Mr. William Wyman and Mr. William Copeland to Board Of Directors
Posted 2014-03-11 23:46NAI Editing
a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Mr. William Wyman and Mr.

Amorfix Chief Scientific Officer Leads the Way for ALS Research
Posted 2014-02-19 23:41NAI Editing
announced today that Dr Neil Cashman, Amorfix Chief Scientific Officer, has published the results of a ground breaking study that shows how ALS is spread throughout the body and has profound implicati

Amorfix Enters into Agreement with a Major Global Pharmaceutical Company for Alzheimer's Disease Diagnostic
Posted 2014-01-22 02:08NAI Editing
announced today that the Company has signed an agreement with a major global pharmaceutical company to use the human Alzheimer's disease diagnostic assay in phase 1 clinical studies.